Filing Flows › Beta Bionics (BBNX) › Q4 2025
Beta Bionics (BBNX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 24, 2026
Beta Bionics (BBNX) reported revenue of $32.1M for the fourth quarter 2025 (Q4 2025), +57% from a year earlier and +18% from the quarter before. Operating margin was -50.2%, net loss $13.5M (41.9% of revenue).
Beta Bionics, Q4 2025: revenue $32.1M (+57% year over year), operating margin -50.2%, net loss $13.5M, operating cash flow −$8.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.1M | +18% | +57% |
| Operating profit | −$16.1M | — | — |
| Net earnings | −$13.5M | — | — |
| Operating cash flow | −$8.6M | — | — |
What changed
Revenue was $32.1M in Q4 2025, up 57% year over year and up 18% from the previous quarter.
Gross margin was 59.0%, up 1.8 points from a year earlier. Operating costs exceeded revenue by $16.1M, an operating margin of -50.2%. Operating expenses grew 42% against revenue growth of 57%. The fastest-growing cost line was General & admin (+83%). The quarter ended with a net loss of $13.5M, narrower than the previous quarter's $14.2M loss.
Operating cash flow was −$8.6M. Non-cash charges added back $538K of depreciation and $4.3M of share-based compensation. Capital expenditures of $1.9M exceeded it, leaving free cash flow of −$10.5M.
Questions
What was Beta Bionics' revenue in the fourth quarter 2025?
Beta Bionics (BBNX) reported revenue of $32.1M for the fourth quarter 2025 (Q4 2025), +57% from a year earlier and +18% from the quarter before.
Was Beta Bionics profitable in the fourth quarter 2025?
Operating loss was $16.1M (-50.2% of revenue) and net loss $13.5M.
Source: Beta Bionics 10-K on SEC EDGAR.